Salem Capital Management’s Johnson & Johnson JNJ Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | $3.4M | Hold |
20,826
| – | – | 2.69% | 14 |
|
|
2022
Q2 | $3.7M | Sell |
20,826
-2,971
| -12% | -$529K | 2.7% | 15 |
|
|
2022
Q1 | $4.22M | Sell |
23,797
-400
| -2% | -$68.1K | 2.37% | 19 |
|
|
2021
Q4 | $4.14M | Sell |
24,197
-84
| -0.3% | -$13.8K | 2.15% | 20 |
|
|
2021
Q3 | $3.92M | Sell |
24,281
-200
| -0.8% | -$34.1K | 2.15% | 19 |
|
|
2021
Q2 | $4.03M | Sell |
24,481
-801
| -3% | -$133K | 2.21% | 17 |
|
|
2021
Q1 | $4.16M | Sell |
25,282
-400
| -2% | -$64.7K | 2.47% | 16 |
|
|
2020
Q4 | $4.04M | Sell |
25,682
-388
| -1% | -$57.3K | 2.57% | 16 |
|
|
2020
Q3 | $3.88M | Sell |
26,070
-1,941
| -7% | -$287K | 2.81% | 13 |
|
|
2020
Q2 | $3.94M | Sell |
28,011
-30
| -0.1% | -$4.37K | 2.82% | 12 |
|
|
2020
Q1 | $3.68M | Sell |
28,041
-3,500
| -11% | -$497K | 3.04% | 11 |
|
|
2019
Q4 | $4.6M | Sell |
31,541
-5,515
| -15% | -$748K | 2.5% | 19 |
|
|
2019
Q3 | $4.79M | Sell |
37,056
-15,890
| -30% | -$2.09M | 2.75% | 14 |
|
|
2019
Q2 | $7.37M | Sell |
52,946
-4,900
| -8% | -$678K | 4.09% | 7 |
|
|
2019
Q1 | $8.09M | Sell |
57,846
-455
| -0.8% | -$60.9K | 4.37% | 6 |
|
|
2018
Q4 | $7.52M | Sell |
58,301
-280
| -0.5% | -$39.1K | 4.74% | 6 |
|
|
2018
Q3 | $8.09M | Buy |
58,581
+26
| +0% | +$3.46K | 4.32% | 6 |
|
|
2018
Q2 | $7.11M | Sell |
58,555
-460
| -0.8% | -$57.4K | 3.81% | 9 |
|
|
2018
Q1 | $7.56M | Sell |
59,015
-700
| -1% | -$94.6K | 4.11% | 8 |
|
|
2017
Q4 | $8.34M | Sell |
59,715
-5,475
| -8% | -$763K | 4.24% | 6 |
|
|
2017
Q3 | $8.47M | Sell |
65,190
-1,250
| -2% | -$166K | 4.37% | 5 |
|
|
2017
Q2 | $8.79M | Sell |
66,440
-275
| -0.4% | -$35.1K | 4.91% | 2 |
|
|
2017
Q1 | $8.31M | Sell |
66,715
-3,700
| -5% | -$442K | 4.61% | 3 |
|
|
2016
Q4 | $8.11M | Sell |
70,415
-550
| -0.8% | -$63.5K | 4.47% | 2 |
|
|
2016
Q3 | $8.38M | Sell |
70,965
-1,820
| -3% | -$221K | 4.6% | 1 |
|
|
2016
Q2 | $8.83M | Sell |
72,785
-2,375
| -3% | -$270K | 5.09% | 1 |
|
|
2016
Q1 | $8.13M | Sell |
75,160
-305
| -0.4% | -$31.6K | 4.57% | 2 |
|
|
2015
Q4 | $7.75M | Buy |
75,465
+1,090
| +1% | +$110K | 4.39% | 3 |
|
|
2015
Q3 | $6.94M | Sell |
74,375
-3,150
| -4% | -$305K | 4.08% | 3 |
|
|
2015
Q2 | $7.56M | Buy |
77,525
+475
| +0.6% | +$47.6K | 3.92% | 3 |
|
|
2015
Q1 | $7.75M | Sell |
77,050
-3,000
| -4% | -$305K | 3.94% | 3 |
|
|
2014
Q4 | $8.37M | Sell |
80,050
-1,350
| -2% | -$142K | 3.98% | 2 |
|
|
2014
Q3 | $8.68M | Sell |
81,400
-665
| -0.8% | -$69K | 4.04% | 2 |
|
|
2014
Q2 | $8.59M | Sell |
82,065
-2,953
| -3% | -$298K | 3.81% | 2 |
|
|
2014
Q1 | $8.35M | Sell |
85,018
-1,825
| -2% | -$169K | 3.66% | 2 |
|
|
2013
Q4 | $7.95M | Sell |
86,843
-1,885
| -2% | -$174K | 3.43% | 3 |
|
|
2013
Q3 | $7.69M | Sell |
88,728
-100
| -0.1% | -$8.97K | 3.54% | 2 |
|
|
2013
Q2 | $7.63M | Buy |
+88,828
| New | +$7.54M | 3.64% | 3 |
|
Other funds holding JNJ
Salem Capital Management's JNJ Position: Q3 2022 in Review
Salem Capital Management held its Johnson & Johnson (JNJ) position steady in Q3 2022 at 20,826 shares worth $3.4M. The position accounts for 2.69% of the portfolio, ranked #14.
Salem Capital Management first reported a position in JNJ in Q2 2013 and has held it in 38 quarters since. The position peaked at $8.83M in Q2 2016. 3,622 funds tracked by Wall St. Rank hold JNJ as of Q3 2022.
- Salem Capital Management held 20,826 shares of Johnson & Johnson worth $3.4M as of Q3 2022.
- Salem Capital Management left its Johnson & Johnson share count unchanged in Q3 2022.
- Johnson & Johnson made up 2.69% of Salem Capital Management's portfolio in Q3 2022, its #14 holding.
- Salem Capital Management first reported a position in Johnson & Johnson in Q2 2013 and has held it in 38 quarters since.
- Salem Capital Management's Johnson & Johnson position peaked at $8.83M in Q2 2016.
- 3,622 funds tracked by Wall St. Rank held Johnson & Johnson as of Q3 2022.
Based on Salem Capital Management's 13F filing for Q3 2022, filed 29 Nov 2022.